Consultants and Scientific Advisors
Dr Thomas Morris – Medical Advisor
Tom is a physician who has worked in pharmaceutical medicine and drug development for over 20 years with much of this time specialising in oncology. After several years working in clinical medicine, he joined firstly Medeval Ltd (University of Manchester) and then AstraZeneca, where he has held a number of global R&D roles. Most recently these included Senior Medical Director and Executive Director Clinical Programs. He has overseen several global drug development programs, interacting with leading external medical and scientific experts, academic groups and regulatory agencies.
Dr Mary Stuart – Medical Advisor
Dr Stuart is Pharmaceutical Physician specialising in oncology, with specific expertise in breast cancer and with over two decades of experience in large multinational pharmaceutical companies. She was the clinical lead for the set up of the positive MonarchE adjuvant breast cancer study for Eli Lilly and the successful Falcon, Olympiad and Olympia studies for AZ, and was the Breast Cancer Disease Area expert for AZ. Previously Mary was clinical lead for the early pertuzumab breast cancer development for Roche.
Professor Albena Dinkova-Kostova – Independent Scientific Advisor
Albena is a Professor of Chemical Biology at the Jacqui Wood Cancer Centre, Division of Cellular Medicine, University of Dundee School of Medicine. She obtained her PhD degree in Biochemistry and Biophysics from Washington State University and then joined the research group of Professor Paul Talalay, who discovered the anti-cancer effect of sulforaphane at Johns Hopkins University back in 1992. She has a core research interest in oxidative stress and inflammation and has published over 100 research papers including many on sulforaphane as an activator of the Nrf2 pathway and as a potential therapeutic strategy for protection against chronic degenerative diseases.
Dr. Sacha Howell – Independent Scientific Advisor
Dr Howell trained in medicine at Nottingham University and in medical oncology at The Christie. He gained his PhD in medical oncology at The University of Manchester in 2006, studying the role of prolactin in breast cancer stem cell regulation. He was appointed Senior Lecturer in Breast Oncology at The University of Manchester in October 2010 and works closely with the basic scientists in the Manchester Breast Centre, focusing on the translation of novel approaches to targeting normal and cancer stem cells into breast cancer prevention and treatment respectively.
Professor Rob Clarke – Independent Scientific Advisor
Professor Clarke is a Professor of Breast Biology and Director of the Manchester Breast Centre, based at the Oglesby Cancer Research Building. His undergraduate BSc studies were in Biology at the University of Sussex and the Université de Grenoble. Following two and half years as a Research Assistant with Chris Potten at the Paterson Institute for Cancer Research, Professor Clarke studied the control of proliferation in the normal and neoplastic human mammary gland for his PhD at The University of Manchester (1995). Subsequently, his post-doctoral training was with Dr Liz Anderson in the Clinical Research Department of The Christie Hospital, Manchester, and in 2001, he returned to The University of Manchester as a Group Leader in the Division of Cancer Sciences. He was Lecturer and Cancer Research UK Research Fellow from 2001-2006, a Senior Lecturer and Breast Cancer Now Research Fellow from 2006-2011 and a Reader in Breast Biology from 2014.
Professor James Chalmers – Independent Scientific Advisor
Professor Chalmers is a Professor and Consultant Respiratory Physician at the School of Medicine, University of Dundee. His laboratory works primarily on the interaction between neutrophils and bacteria during acute and chronic airway infections. Major areas of research with relevance to AMR include phase 1 and phase 2 studies of non-antibiotic alternative therapies for respiratory infections, the development of diagnostics to reduce antibiotic use by more accurately identifying bacterial infections and work to understand the selective drivers of antimicrobial resistance in chronic airways diseases such as bronchiectasis and cystic fibrosis where multidrug resistant Gram-negative infections are common. His work is funded by the Wellcome Trust, Medical Research Council, Scottish Government, EU and the pharmaceutical industry.
Professor Phil Eaton – Independent Scientific Advisor
Professor Eaton gained a BSc in Biochemistry from Queen Mary College, University of London in 1989 before completing his PhD studies at the University of Sussex. After post-doctoral work at the Institute of Psychiatry, he joined the Department of Cardiovascular Research at the Rayne Institute, St Thomas’ Hospital in 1995. He remained there for nearly 24 years within the School of Cardiovascular Medicine & Sciences at King’s College London. In 2019 he moved to the William Harvey Research Institute, Queen Mary University of London where he heads a group studying the molecular basis of redox sensing and signalling in the cardiovascular system.